JTH: New Data Exposes Wide Variation in U.S. Perioperative Bleeding Management
Journal of Thrombosis and Haemostasis (JTH) posted on LinkedIn:
”Perioperative use of factor concentrates and blood products – a survey of clinical practices in the United States
By Jerrold Levy, Joseph R. Shaw, Kamrouz Ghadimi, Cheryl Maier, Douketis James, Keyvan Karkouti, Michael Mazzeffi, Alex C Spyropoulos, MD, FACP, FCCP, FRCPC, Kenichi Tanaka, Jean Connors, and Roman Sniecinski
The management of perioperative bleeding and anticoagulant reversal is rapidly evolving, shaped by new education initiatives and expanding availability of factor concentrates.
4-factor PCCs were the preferred therapy for warfarin and DOAC reversal in emergency surgery and major bleeding (used by >70%).
Cryoprecipitate remained the dominant source of fibrinogen replacement (66%), while access to fibrinogen concentrate was limited.
FFP continued as the first-line product for factor replacement in cardiac (60%), hepatic (67%), and postpartum hemorrhage (71%).
These data show a steady shift toward PCC-centric reversal strategies, with persistent heterogeneity in fibrinogen replacement and factor support across US perioperative settings.
Read the article here.”
Title: Perioperative use of factor concentrates and blood products—a survey of clinical practices in the United States: communication from the ISTH Subcommittee on Perioperative and Critical Care
Authors: Jerrold H. Levy, Joseph R. Shaw, Kamrouz Ghadimi, Cheryl L. Maier, James Douketis, Keyvan Karkouti, Michael Mazzeffi, Alex C. Spyropoulos, Kenichi A. Tanaka, Jean M. Connors, Roman M. Sniecinski
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025